Content hub
ASCO 2025 Roundup
Essential insights for cancer’s biggest meeting.
Access vital insights, critical updates, and penetrating analysis about the 2025 annual meeting of the American Society of Clinical Oncology (ASCO) from the team of expert healthcare analysts and journalists designed to support your decision-making from pre-event to post-event impact.
Pre-ASCO Report
ASCO Weekend Update
Post-ASCO Report
Get full access to ASCO analysis
Datamonitor Healthcare
Datamonitor Healthcare empowers you to understand the future market potential of assets in development and how they will impact the market.
Biomedtracker
Biomedtracker provides analysis of major market-moving events, the drugs pipeline, deals and more in the pharma and biotech industries.
Related Insights
Article
02 June 2025
ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
Article
31 May 2025
ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing
Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.
Article
02 June 2025
ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP
Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.
Article
02 June 2025
ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
ARCHIVE
Explore More Coverage from Scrip
Ready to see how Evaluate can help you make smarter decisions?
Get in touch with our team to explore the right solutions for your business.